Applicant, as named in the Orange Book

Biocryst

Next listed expiry: Rapivab on 7 May 2027. 3 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Rapivab peramivir	peramivir	206426	7 May 2027	patent, carve-out possible
Orladeyo · 2 strengths berotralstat dihydrochloride	berotralstat dihydrochloride	214094	1 May 2040	patent
Orladeyo · 4 strengths berotralstat dihydrochloride	berotralstat dihydrochloride	219776	1 May 2040	patent

24 Oct 2026Rapivab · Enters 12-month window basis: patent, carve-out possible7 May 2027